期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

CAR-T对肿瘤的特异性治疗研究进展 被引量：1

Research Progress of CAR-T Specific Therapy to Tumor
下载PDF
导出
摘要 嵌合抗原受体T细胞免疫疗法(CAR-T疗法)是一种治疗肿瘤的新免疫疗法,通过向患者自身T细胞中导入已被修饰的CAR基因,使T细胞表达结合肿瘤表面抗原的特异性受体来实现对肿瘤的精准治疗.目前已发展到第四代.该免疫疗法在血液瘤和实体瘤治疗中都有一定疗效,同时也存在一些待解决难题.本文就近年来CAR-T在血液瘤和实体瘤中的研究治疗进展及存在的问题进行综述. CAR-T therapy is a novel therapy to treat tumors.It has realized the precise treatment of tumors by transforming the modified CAR gene into patients’self T cells,driving the T cells expressing specific antibodies which are able to bind surface antigens to tumors.CAR-T has been in its fourth generation since put forward.This therapy exists both certain effects and risks in blood tumors as well as solid tumors but exposes some difficulty waited to be solved.In this review,we describe the treatment and existing problems of CAR-T therapy in blood tumors and solid tumors.
作者 梅恩典 马佳兵 高佳东 刘轶轩 钱程 刘立 魏旭斌 MEI En-Dian;MA Jia-Bing;GAO Jia-Dong;LIU Yi-Xuan;QIAN Cheng;LIU Li;WEI Xu-Bin(School of Life Science,Zhejiang Sci-Tech University,Hangzhou 310018,China)
机构地区 浙江理工大学生命科学学院
出处 《生物化学与生物物理进展》 SCIE CAS CSCD 北大核心 2019年第4期333-341,共9页 Progress In Biochemistry and Biophysics
基金 浙江省自然科学基金资助项目(LY15H280015) 浙江省科技厅公益项目(2016C37012) 浙江理工大学科研启动基金资助项目(15042087-Y)~~
关键词 CAR-T 急性淋巴细胞白血病 实体瘤 免疫治疗 肿瘤微环境 CAR-T acute lymphoblastic leukemia solid tumor immunotherapy tumor microenvironment
分类号 R730.51 [医药卫生—肿瘤]
  • 相关文献

参考文献1

二级参考文献42

  • 1Brentjens, R., Yeh, R., Bernal, Y., Riviere, I., and Sadelain, M. (2010). Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. Mol Ther 18, 666-668.
  • 2Brentjens, R.J., Davila, M.L., Riviere, I., Park, J., Wang, X., Cowell, L.G.,I Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., Borquez-OjedaI O., Qu, J., Wasielewska, T., He, Q., Bernal, Y., Rijo, LV., Hedvat, C.I Kobos, R., Curran, K., Steinherz, P., Jurcic, J., Rosenblat, T., MaslakI P., Frattini, M., and Sadelain, M. (2013). CD19-targeted T cells rapidl induce molecular remissions in adults with chemotherapy-refractor acute lymphoblastic leukemia. Sci Transl Med 5, 177ra138. |.
  • 3Brentjens, R.J., Riviere, I., Park, J.H., Davila, M.L., Wang, X., Stefanski, J., Taylor, C., Yeh, R., Bartido, S., Borquez-Ojeda, O., Olszewska, M., Bernal, Y., Pegram, H., Przybylowski, M., Hollyman, D., Usachenko, Y., Pirraglia, D., Hosey, J., Santos, E., Halton, E., Maslak, P., Schein- berg, D., Jurcic, J., Heaney, M., Heller, G., Frattini, M., and Sadelain, M. (2011). Safety and persistence of adoptively transferred autologous CD19-targeted T ceils in patients with relapsed or chemotherapy re- fractory B-cell leukemias. Blood 118, 48174828.
  • 4Brentjens, R.J., Santos, E., Nikhamin, Y., Yeh, R., Matsushita, M., La Perle, K., Quintas-Cardama, A., Larson, S.M., and Sadelain, M. (2007). Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin Cancer Res 13, 5426-5435.
  • 5Carpenito, C., Milone, M.C., Hassan, R., Simonet, J.C., Lakhal, M., Suhoski, M.M., Varela-Rohena, A., Haines, K.M., Heitjan, D.F., A1- belda, S.M., Carroll, R.G., Riley, J.L., Pastan, I., and June, C.H. (2009). Control of large, established tumor xenografts with genetically retar- geted human T ceils containing CD28 and CD137 domains. Proc Natl Acad Sci USA 106, 3360-3365.
  • 6Caserta, S., Alessi, P., Basso, V., and Mondino, A. (2010). IL-7 is superior to IL-2 for ex vivo expansion of tumour-specific CD4+ T cells. Eur J Immuno140, 470-479.
  • 7Cruz, C.R., Micklethwaite, K.P., Savoldo, B., Ramos, C.A., Lam, S., Ku, S., Diouf, O., Liu, E., Barrett, A.J., Ito, S., Shpall, E.J., Krance, R.A., Kamble, R.T., Carrum, G., Hosing, C.M., Gee, A.P., Mei, Z., Grilley, B.J., Heslop, H.E., Rooney, C.M., Brenner, M.K., Bollard, C.M., and Dotti, G. (2013). Infusion of donor-derived CD19-redirected vi- rus-specific T ceils for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood 122, 2965-2973.
  • 8Cui, Y., Zhang, H, Meadors, J., Poon,-R., Guimond, M., and Mackall, C.L. (2009). Harnessing the physiology of lymphopenia to support adoptiv immunotherapy in lymphoreplete hosts. Blood 114, 3831-3840. |.
  • 9Curran, K.J., Seinstra,'B.)k., Nikhamin, Y., Yeh, R., Usachenko, Y., van Leeuwen, D.G., Purdon, T., Pegram, H.J., and Brentjens, R.J. (2015). Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression. Mol Ther 23,769-778.
  • 10Davila, II.L., Riviere, I., Wang, X., Bartido, S., Park, J., Curran, K., Chung, S.S., Stefanski, J., Borquez-Ojeda, O., Olszewska, M., Qu, J., Wasielewska, T., He, Q., Fink, M., Shinglot, H., Youssif, M., Satter, M., Wang, Y., Hosey, J., Quintanilla, H., Halton, E., Bernal, Y., Bou- hassira, D.C., Arcila, M.E., Gonen, M., Roboz, G.J., Maslak, P., Douer, D., Frattini, M.G., Giralt, S., Sadelain, M., and Brentjens, R. (2014). Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Meal 6, 224ra225.

共引文献10

引证文献1

二级引证文献3

生物化学与生物物理进展
2019年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部